Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $38.00 by Analysts at Wells Fargo & Company

Sarepta Therapeutics (NASDAQ:SRPT) had its price target lowered by Wells Fargo & Company from $45.00 to $38.00 in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock.

Several other equities analysts also recently commented on SRPT. Wedbush boosted their price objective on Sarepta Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Robert W. Baird cut their price objective on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a report on Tuesday, January 27th. Piper Sandler raised their target price on shares of Sarepta Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Finally, Barclays began coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 price objective for the company. Nine investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have given a Sell rating to the company. According to MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $33.56.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT traded down $0.69 during trading hours on Friday, hitting $16.76. 2,616,163 shares of the stock traded hands, compared to its average volume of 2,282,218. The company has a market cap of $1.76 billion, a price-to-earnings ratio of -1.99, a price-to-earnings-growth ratio of 0.44 and a beta of 0.39. Sarepta Therapeutics has a 1 year low of $10.41 and a 1 year high of $108.48. The stock has a 50 day moving average price of $20.43 and a 200 day moving average price of $20.21. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The firm had revenue of $442.93 million for the quarter, compared to the consensus estimate of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 49.42%. The firm’s revenue for the quarter was down 32.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.90 earnings per share. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Sarepta Therapeutics by 9.2% in the fourth quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock worth $254,167,000 after buying an additional 993,283 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 454.6% in the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after acquiring an additional 6,390,860 shares during the period. Erste Asset Management GmbH raised its stake in shares of Sarepta Therapeutics by 1.6% in the fourth quarter. Erste Asset Management GmbH now owns 2,728,945 shares of the biotechnology company’s stock valued at $58,727,000 after acquiring an additional 43,000 shares during the period. Aberdeen Group plc lifted its holdings in shares of Sarepta Therapeutics by 13.6% in the 4th quarter. Aberdeen Group plc now owns 2,251,593 shares of the biotechnology company’s stock worth $48,454,000 after acquiring an additional 268,829 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of Sarepta Therapeutics by 2.7% during the 4th quarter. First Trust Advisors LP now owns 1,992,577 shares of the biotechnology company’s stock worth $42,880,000 after purchasing an additional 52,796 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue beat estimates in Q4 ($442.9M vs. ~$391M consensus), which partially offsets earnings weakness and suggests underlying commercial traction outside the challenged product. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Wells Fargo kept an “overweight” rating on SRPT, implying continued analyst conviction in the story despite lowering its price target to $38 (from $45), signaling potential upside from current levels. Wells Fargo Lowers Price Target
• Neutral Sentiment: Sarepta expanded non-market PR and community programs — opening applications for the Route 79 Duchenne scholarship — which supports brand and patient-community relations but is unlikely to move near-term valuation. Sarepta Announces Route 79 Scholarship
• Neutral Sentiment: Sarepta plans to present long-term and safety data at the upcoming MDA conference — data releases could be material but timing and contents are uncertain. Sarepta to Present Long-Term Data at MDA
• Negative Sentiment: Large Q4 EPS miss: reported EPS was far worse than consensus (reported loss −$3.58 vs. est. −$0.87), driven by a steep decline in ELEVIDYS sales and a wider net loss, increasing short-term revenue and margin uncertainty. Sarepta Q4 Earnings Report
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon his replacement), introducing leadership transition risk at a sensitive time for product recovery and strategy execution. Reuters: Sarepta CEO Ingram to Retire
• Negative Sentiment: Institutional selling: AXQ Capital materially trimmed its SRPT stake (large percentage reduction), which can add selling pressure and signal reduced conviction among some holders. AXQ Capital Lowers Position in Sarepta

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.